Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation

Journal of Clinical Pharmacy and Therapeutics
Hiroko Kato-HayashiAkio Suzuki

Abstract

Patients who receive hematopoietic stem cell transplantation (HSCT) are usually administered a calcineurin inhibitor. Because vancomycin is associated with an increased incidence of nephrotoxicity, neutropenic patients receiving HSCT are considered a high-risk population for nephrotoxicity with vancomycin. We retrospectively compared the efficacy and safety of vancomycin and teicoplanin in febrile neutropenic patients receiving HSCT. A single-centre, retrospective cohort study was conducted at the 614-bed Gifu University Hospital in Japan. Patients who received HSCT and were administered vancomycin or teicoplanin by injection for febrile neutropenia from 1 January 2012 to 31 August 2017 were enrolled. Time to attain an effective trough concentration, clinical efficacy and adverse events were compared between the two groups. Time to attain an effective trough concentration of over 10 μg/mL tended to be shorter in the teicoplanin group than in the vancomycin group (median 3, 95% confidence interval [CI] 2.4-3.6 days vs median 6, 95% CI 1.5-10.5 days; hazard ratio [HR] 0.4, 95% CI 0.15-1.06; P = .066). The rate of clinical failure was lower in the teicoplanin group than in the vancomycin group (18.8% vs 53.8%, P = .113). In additi...Continue Reading

References

Jan 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A MicozziP Martino
Feb 1, 1996·The Journal of Antimicrobial Chemotherapy·M J Wood
Apr 26, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Feb 11, 2005·Chemical Reviews·Dan KahneChristopher Walsh
Jan 18, 2006·Biochemical Pharmacology·John L Pace, Guang Yang
Oct 12, 2007·The New England Journal of Medicine·Frederick R Appelbaum
Jul 15, 2009·Antimicrobial Agents and Chemotherapy·Shuli SvetitskyMical Paul
Jan 6, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·UNKNOWN Japanese Society of ChemotherapyKohya Shiba
Nov 9, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Takashi UedaMotoi Uchino
Jun 11, 2014·Blood·Shernan G HoltanDaniel J Weisdorf
Jun 25, 2017·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Shinichi WatanabeTakuro Kanekura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.